LOGO
LOGO

Email This Article

Oxford BioMedica H1 Loss Narrows; Revenue Up 44%; Backs FY25, Medium-Term View; Stock Up
To Email: *
Bcc: Seperate multiple addresses with commas(,)
Your Email: *
Format :

* Denotes Required Fields